… The absolute bioavailability of dabigatran after oral administration of dabigatran etexilate is
6… Table 2 shows the pharmacokinetic parameters of dabigatran etexilate administered orally. …

… Dabigatran etexilate is a novel and potent nonpeptidic direct thrombin inhibitor Food and …
There is a lack of extensive data regarding the clinical pharmacokinetics, pharmacodynamics, …

… and 32 clinical data on DOACs especially in older adults with geriatric profile. This is highly
relevant as 33 pharmacokinetics and pharmacodynamics (… in pharmacokinetics of direct oral …

… Our findings expand the available clinical evidence about the pharmacokinetic properties
of DOACs among patients with extreme obesity and AF and support the hypothesis that the …

… However, relatively limited data exist on the clinical pharmacokinetics (PK), pharmacodynamics
(PD), efficacy, and safety in patients with morbid obesity (body mass index [BMI] of ≥40 …

… Currently, a direct thrombin inhibitor dabigatran, and several direct factor Xa inhibitors (FXaI)—…
Dabigatran etexilate is the first direct oral anticoagulant approved for the treatment of …

… oral medication classes being direct factor Xa inhibitors (DFXaI) and direct thrombin inhibitors
(… via their own clinical trials (11), with rivaroxaban and dabigatran etexilate being amongst …

… Dabigatran etexilate is an oral, non–vitamin K-dependent, direct thrombin inhibitor approved
for prevention of thromboembolic events in patients with atrial fibrillation (AF). However, …

… oral anticoagulation use in Chinese patients with AF in recent years [2,3,4,5]. Dabigatran
etexilate, an oral direct thrombin inhibitor, … warfarin, dabigatran etexilate demonstrated superior …

… the direct thrombin inhibitor dabigatran, are prescribed at fixed doses and do not require
routine therapeutic drug monitoring. Accurate determination of dabigatran … Dabigatran etexilate …